NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

CHIMERIC THERAPEUTICS LIMITED (CHM)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of CHM: rating 2
(2 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000121576
Address: Level 3, 62 Lygon Street Carlton South Vic 3053, Australia
Tel:  +61 3 98245254

Date first listed: 18/01/2021

Activities: Chimeric is a biotechnology company developing a cancer cell therapy drug

News & Events

Expand this box to read and print

The suspension of trading in the securities of Chimeric Therapeutics Limited will be lifted immediately following the release by CHM of an announcement regarding a capital raising that was not undertaken and subsequently an intention to conduct an entitlement offer.

04/03/2025

The company plans to undertake an Entitlement Offer to raise $3.2 million at a pro rata non-renounceable price of $0.005 per share. The offer will be completed by issuing 2 new shares for every 5 existing shares held by eligible shareholders. The funds will support the development of Chimeric's CHM CDH17 Phase 1/2 clinical trial. The offer is subject to shareholder approval.

04/03/2025

The securities of Chimeric Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CHM, pending the release of an announcement regarding a capital raising.

03/03/2025

The suspension of trading in the securities of Chimeric Therapeutics Limited will be lifted from the commencement of trading on Tuesday, 22 October 2024 following lodgement of its annual report for the year ended 30 June 2024.

21/10/2024

The company lodges its Environmental Social Governance Report.

21/10/2024

The company lodges its Corporate Governance Statement and Appendix 4G.

21/10/2024

The company lodges its 2024 Annual Report.

21/10/2024

The company has received commitments for a $5 million capital raising through a two-tranche placement to sophisticated investors. The offer price is $0.008 per Placement Share, with 125 million Placement Shares to be issued to Executive Chairman Paul Hopper. The remaining shares will be issued at an extraordinary general meeting. The placement is expected to occur on 23 October 2024, with normal trading starting on 24 October 2024.

21/10/2024

The Annual General Meeting of the company will take place on November 12, 2024, at Level 3, 62 Lygon Street, Carlton, Victoria 3053, with registration starting at 10:45 am.

14/10/2024

The company lodges its 2024 Annual Report update.

11/10/2024

The company has reported a Complete Response from an Acute Myelogenous Leukemia patient in its CHM CORE-NK + Vactosertib Phase 1b clinical trial. The trial, led by Dr Eva Selfridge at UH Seidman Cancer Center in Ohio, is the first to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The patient will continue on study and be monitored for up to 15 years, a standard FDA requirement for all cell therapy trials. The trial is currently enrolled in three patients, with the goal of enrolling 12 patients.

07/10/2024

The company lodges its 2024 Annual Report update.

04/10/2024

The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 1 October 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Monday, 30 September 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

01/10/2024

The suspension of trading in the options (ASX: CHMO) of Chimeric Therapeutics Limited will be lifted immediately.

28/03/2022

The options of Chimeric Therapeutics Limited will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made available for them, as noted in CHM's Prospectus, announced to the market on 21 February 2022. The options are expected to be quoted on a normal settlement basis on Monday, 28 March 2022. The suspension only applies to the CHM's options and does not apply to any other quoted securities of CHM.

21/03/2022

listed entity carried for record purposes only

18/01/2021

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    04/07/2022George Matcham342,070$0.098$33,523
    29/06/2022Leslie Chong30,000$0.098$2,940
    03/12/2021Paul Hopper375,000$0.263$98,438
    04/08/2021George Matcham500,000$0.335$167,500
    08/03/2021Cindy Elkins24,800$0.318$7,881

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Paul HopperExecutive Chairman04/02/2020
    Rebecca McQualterCEO12/11/2024
    Phillip HainsCFO, Company Secretary06/10/2020
    Lesley RussellNon Exec Director18/01/2021
    Eric SullivanNon Exec Director30/08/2023
    Nathan JongCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Jennifer ChowManaging Director, CEO30/08/202124/05/2024
    Cindy ElkinsNon Exec Director01/02/202130/08/2023
    George MatchamNon Exec Director05/07/202103/08/2023
    Leslie ChongNon Exec Director18/01/202112/07/2023

    Date of first appointment, title may have changed.